The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Some Companies Postpone April Personnel Changes due to Earthquake
April 11, 2011
- Abbott Japan Completes Acquisition of Former Solvay Pharm.
April 11, 2011
- OncoTherapy Starts PII Trial of Angiogenesis Inhibitor
April 11, 2011
- Eisai Licenses Bexarotene to Minophagen
April 11, 2011
- P&G, Teva to Combine Their OTC Businesses
April 11, 2011
- OncoTherapy Begins Recruitment for Cancer Vaccine Trial
April 11, 2011
- Eisai Enters Collaborative R&D Agreement with PRISM BioLab
April 11, 2011
- BI Japan Starts Operations
April 11, 2011
- Collategene Shrinks Ulcers in Buerger's Disease Patients: AnGes MG
April 11, 2011
- Astellas Licenses 3 Compounds to Cardeus
April 11, 2011
- Actos's Use Patent Valid for Combination with α-GIs, SUs, But Not BGs
April 11, 2011
- Mirabegron Improves Key OAB Symptoms in PIII Trial: Astellas
April 11, 2011
- Ono Licenses Cancer Peptide Vaccines from OncoTherapy
April 11, 2011
- Astellas, Pfizer Apply for Additional Indications for Celecox
April 11, 2011
- 5 Remaining Unapproved Drugs/Indications Find Development Sponsors
April 11, 2011
- Wakamoto Aims to Return to Black in FY2011: New President Kamiya
April 11, 2011
- AnGes MG Licenses Transdermal Formulation Technology from MEDRx
April 11, 2011
- Generic Market Share to Reach 6.1% for 2010: Fuji-Keizai
April 11, 2011
- Takeda, DSP Announce Collaboration for Lurasidone in Europe
April 11, 2011
- AXIS Licenses Pilocarpine to Kissei for Development as Fibromyalgia Treatment: SNBL
April 11, 2011
ページ
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…